Vera Therapeutics (VERA) 10-Q 7 Nov 24 2024 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2024	Nov. 05, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Trading Symbol	VERA
Entity Registrant Name	Vera Therapeutics, Inc.
Entity Central Index Key	0001831828
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Class A common stock, $0.001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-40407
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-2744449
Document Quarterly Report	true
Document Transition Report	false
Entity Address, Address Line One	2000 Sierra Point Parkway
Entity Address, Address Line Two	Suite 1200
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	650
Local Phone Number	770-0077
Entity Common Stock, Shares Outstanding		63,323,053

Condensed Balance Sheet

Condensed Balance Sheet - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 27,256	$ 45,681
Marketable securities	326,053	115,035
Prepaid expenses and other assets, current	10,822	11,307
Total current assets	364,131	172,023
Property and equipment, net	368	92
Operating lease right-of-use assets	3,921	2,949
Prepaid expenses and other assets, noncurrent	140	482
Total assets	368,560	175,546
Current liabilities:
Accounts payable	4,602	11,118
Operating lease liabilities	1,872	2,436
Accrued expenses and other liabilities, current	19,990	8,749
Total current liabilities	26,464	22,303
Long-term debt	50,470	49,877
Operating lease liabilities, noncurrent	2,568	1,395
Accrued expenses and other liabilities, noncurrent	0	286
Total liabilities	79,502	73,861
Stockholders' equity
Preferred stock, $0.001 par value; 10,000,000 authorized as of September 30, 2024 and December 31, 2023; no shares issued and outstanding as of September 30, 2024 and December 31, 2023	0	0
Class A common stock, $0.001 par value; 500,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 55,026,111 and 44,452,161 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	55	44
Additional paid-in capital	705,784	410,492
Accumulated other comprehensive income	1,044	251
Accumulated deficit	(417,825)	(309,102)
Total stockholders' equity	289,058	101,685
Total liabilities and stockholders' equity	$ 368,560	$ 175,546

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock par or stated value per share	$ 0.001	$ 0.001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common Class A [Member]
Common stock, Par value	$ 0.001	$ 0.001
Common stock, Shares authorized	500,000,000	500,000,000
Common stock, Shares issued	55,026,111	44,452,161
Common stock, Shares outstanding	55,026,111	44,452,161

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 40,314	$ 16,100	$ 92,825	$ 57,440
General and administrative	9,487	5,656	25,431	17,544
Total operating expenses	49,801	21,756	118,256	74,984
Loss from operations	(49,801)	(21,756)	(118,256)	(74,984)
Other income (expense):
Interest income	4,761	2,158	14,051	6,019
Interest expense	(1,936)	(943)	(5,755)	(2,730)
Other income, net	344	437	1,237	1,360
Total other income	3,169	1,652	9,533	4,649
Net loss	(46,632)	(20,104)	(108,723)	(70,335)
Other comprehensive income:
Change in unrealized gains and losses on marketable securities	1,494	67	793	149
Comprehensive loss	$ (45,138)	$ (20,037)	$ (107,930)	$ (70,186)
Net loss per share attributable to common stockholders, basic	$ (0.85)	$ (0.45)	$ (2.03)	$ (1.67)
Net loss per share attributable to common stockholders, diluted	$ (0.85)	$ (0.45)	$ (2.03)	$ (1.67)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	54,898,297	44,363,419	53,537,910	42,124,779
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	54,898,297	44,363,419	53,537,910	42,124,779

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Common Class A [Member] Common Stock [Member]
Beginning balances, shares at Dec. 31, 2022					27,800,861
Beginning Balances, Value at Dec. 31, 2022	$ 76,908	$ 290,216	$ (224)	$ (213,112)	$ 28
Issuance of common stock from underwritten follow-on offering, net of offering costs, shares					16,428,572
Issuance of common stock from underwritten follow-on offering, net of offering costs	107,743	107,727			$ 16
Issuance of common stock pursuant to exercise of options	65	65
Issuance of common stock pursuant to exercise of options, shares					3,750
Issuance of common stock pursuant to employee stock purchase plan, shares					27,926
Issuance of common stock pursuant to employee stock purchase plan value	175	175
Stock-based compensation	2,667	2,667
Unrealized gain (loss) on marketable securities	220		220
Net Income (Loss)	(30,069)			(30,069)
Ending Balances, shares at Mar. 31, 2023					44,261,109
Ending Balances, Value at Mar. 31, 2023	157,709	400,850	(4)	(243,181)	$ 44
Beginning balances, shares at Dec. 31, 2022					27,800,861
Beginning Balances, Value at Dec. 31, 2022	76,908	290,216	(224)	(213,112)	$ 28
Proceeds from short swing settlement	0
Net Income (Loss)	(70,335)
Ending Balances, shares at Sep. 30, 2023					44,432,945
Ending Balances, Value at Sep. 30, 2023	123,707	407,185	(75)	(283,447)	$ 44
Beginning balances, shares at Mar. 31, 2023					44,261,109
Beginning Balances, Value at Mar. 31, 2023	157,709	400,850	(4)	(243,181)	$ 44
Issuance of common stock pursuant to exercise of options	432	432
Issuance of common stock pursuant to exercise of options, shares					44,820
Issuance of common stock upon vesting of restricted stock units, shares					2,500
Stock-based compensation	2,682	2,682
Unrealized gain (loss) on marketable securities	(138)		(138)
Net Income (Loss)	(20,162)			(20,162)
Ending Balances, shares at Jun. 30, 2023					44,308,429
Ending Balances, Value at Jun. 30, 2023	140,523	403,964	(142)	(263,343)	$ 44
Issuance of common stock pursuant to exercise of options	197	197
Issuance of common stock pursuant to exercise of options, shares					45,078
Issuance of common stock upon vesting of restricted stock units, shares					62,884
Issuance of common stock pursuant to employee stock purchase plan, shares					16,554
Issuance of common stock pursuant to employee stock purchase plan value	101	101
Stock-based compensation	2,923	2,923
Unrealized gain (loss) on marketable securities	67		67
Net Income (Loss)	(20,104)			(20,104)
Ending Balances, shares at Sep. 30, 2023					44,432,945
Ending Balances, Value at Sep. 30, 2023	123,707	407,185	(75)	(283,447)	$ 44
Beginning balances, shares at Dec. 31, 2023					44,452,161
Beginning Balances, Value at Dec. 31, 2023	101,685	410,492	251	(309,102)	$ 44
Issuance of common stock from underwritten follow-on offering, net of offering costs, shares					9,274,194
Issuance of common stock from underwritten follow-on offering, net of offering costs	269,592	269,583			$ 9
Issuance of common stock pursuant to exercise of options	6,613	6,612			$ 1
Issuance of common stock pursuant to exercise of options, shares					708,897
Issuance of common stock upon vesting of restricted stock units, shares					938
Issuance of common stock pursuant to employee stock purchase plan, shares					21,181
Issuance of common stock pursuant to employee stock purchase plan value	298	298
Proceeds from short swing settlement	37	37
Stock-based compensation	4,124	4,124
Unrealized gain (loss) on marketable securities	(424)		(424)
Net Income (Loss)	(28,383)			(28,383)
Ending Balances, shares at Mar. 31, 2024					54,457,371
Ending Balances, Value at Mar. 31, 2024	353,542	691,146	(173)	(337,485)	$ 54
Beginning balances, shares at Dec. 31, 2023					44,452,161
Beginning Balances, Value at Dec. 31, 2023	101,685	410,492	251	(309,102)	$ 44
Proceeds from short swing settlement	37
Net Income (Loss)	(108,723)
Ending Balances, shares at Sep. 30, 2024					55,026,111
Ending Balances, Value at Sep. 30, 2024	289,058	705,784	1,044	(417,825)	$ 55
Beginning balances, shares at Mar. 31, 2024					54,457,371
Beginning Balances, Value at Mar. 31, 2024	353,542	691,146	(173)	(337,485)	$ 54
Issuance of common stock pursuant to exercise of options	3,439	3,438			$ 1
Issuance of common stock pursuant to exercise of options, shares					358,265
Issuance of common stock upon vesting of restricted stock units, shares					937
Stock-based compensation	4,873	4,873
Unrealized gain (loss) on marketable securities	(277)		(277)
Net Income (Loss)	(33,708)			(33,708)
Ending Balances, shares at Jun. 30, 2024					54,816,573
Ending Balances, Value at Jun. 30, 2024	327,869	699,457	(450)	(371,193)	$ 55
Issuance of common stock pursuant to exercise of options	505	505
Issuance of common stock pursuant to exercise of options, shares					100,628
Issuance of common stock upon vesting of restricted stock units, shares					105,597
Issuance of common stock pursuant to employee stock purchase plan, shares					7,763
Issuance of common stock pursuant to employee stock purchase plan value	247	247
Repurchase of common stock	(13)	(13)
Repurchase of common stock, shares					(4,450)
Stock-based compensation	5,588	5,588
Unrealized gain (loss) on marketable securities	1,494		1,494
Net Income (Loss)	(46,632)			(46,632)
Ending Balances, shares at Sep. 30, 2024					55,026,111
Ending Balances, Value at Sep. 30, 2024	$ 289,058	$ 705,784	$ 1,044	$ (417,825)	$ 55

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (108,723)	$ (70,335)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	50	17
Accretion of discount and amortization of premium on purchase of debt securities	(6,906)	(3,168)
Accretion of loan exit fee and amortization of loan costs	593	232
Reduction in the carrying amount of operating lease right-of-use assets	1,516	1,692
Stock-based compensation	14,585	8,272
Changes in operating assets and liabilities:
Prepaid expense and other current assets	485	(636)
Other assets	342	(263)
Accounts payable	(6,516)	309
Accrued and other liabilities	10,955	(1,161)
Operating lease liabilities	(1,878)	(1,996)
Net cash used in operating activities	(95,497)	(67,037)
Cash flows from investing activities
Purchase of property and equipment	(327)	0
Purchase of marketable securities	(409,000)	(171,730)
Proceeds from maturities of marketable securities	201,681	104,200
Proceeds from sale of marketable securities	4,000	9,543
Net cash used in investing activities	(203,646)	(57,987)
Cash flows from financing activities
Proceeds from exercise of stock options and employee stock purchase plan	11,102	969
Proceeds from short swing settlement	37	0
Repurchase of common stock	(13)	0
Proceeds from issuance of Class A common stock in follow-on offering	287,500	115,000
Payment of costs and underwriting discounts and commissions related to follow-on offering	(17,908)	(7,256)
Net cash provided by financing activities	280,718	108,713
Net decrease in cash and cash equivalents	(18,425)	(16,311)
Cash and cash equivalents, beginning of period	45,681	43,752
Supplemental disclosure of cash flow information
Cash paid for interest expense	4,990	2,499
Cash paid for operating leases	2,343	2,238
Addition to right-of-use assets obtained from operating lease liabilities	2,487	0
Cash and cash equivalents [Member]
Cash flows from financing activities
Cash and cash equivalents, end of period	$ 27,256	$ 27,441

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (46,632)	$ (33,708)	$ (28,383)	$ (20,104)	$ (20,162)	$ (30,069)	$ (108,723)	$ (70,335)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Description of

Organization and Description of the Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of the Business	1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS Description of Business Vera Therapeutics, Inc. (the Company) is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware. The Company’s headquarters and operations are located in Brisbane, California. The Company operates in one segment. Liquidity Since inception, the Company devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. The Company has incurred recurring net operating losses and has not generated positive cash flow from operations since its inception and had an accumulated deficit of $ 417.8 million as of September 30, 2024. The Company had cash, cash equivalents and marketable securities of $ 353.3 million as of September 30, 2024. The Company has funded its operations primarily through the issuance of common stock, redeemable convertible preferred stock, debt financing and convertible notes. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years. Management believes that the Company’s cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months subsequent to the issuance date of these financial statements. The Company intends to raise additional capital through public or private equity offerings or debt financing or other capital sources, which may include strategic collaborations or other arrangements with third parties in order to achieve its long-term business objectives. If the Company fails to obtain necessary capital when needed on acceptable terms, or at all, it could force the Company to delay, limit, reduce or terminate its product development programs, commercialization efforts or other operations .

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (the SEC) regarding interim financial reporting. The U.S. dollar is the Company’s functional and reporting currency. Unaudited Condensed Financial Statements In the opinion of management, the unaudited condensed financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the periods presented. Interim results are not necessarily indicative of results for a full year or any other period. The information included in this Form 10-Q should be read in conjunction with the audited financial statements and related notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 27, 2024. Emerging Growth Company Status T he Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Use of Estimates The preparation of the Company’s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the accrual of research and development expenses, valuation of equity awards for stock-based compensation, determination of incremental borrowing rate for operating leases, the valuation allowance for deferred tax assets, and fair value of marketable and non-marketable securities. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates. Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations. The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fails to satisfy the Company’s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect operating results. The Company’s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies from the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 . Recently Adopted Accounting Pronouncements In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard update clarifies the guidance in Topic 210, related to measuring the fair value of an equity security subject to contractual sale restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The guidance is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company adopted this standard on January 1, 2024, and it did not have a material impact on the Company’s condensed financial statements or related disclosures . Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements and requires enhanced disclosures related to significant segment expenses regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. This ASU will result in the required additional disclosures being included in the Company’s financial statements upon adoption. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in the Company’s financial statements upon adoption .

Other Financial Statement Infor

Other Financial Statement Information	9 Months Ended
	Sep. 30, 2024
Other Financial Statement Information [Abstract]
Other Financial Statement Information	3. OTHER FINANCIAL STATEMENT INFORMATION Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, Prepaid clinical trial costs $ 3,825 $ 5,273 Interest income receivable 1,997 512 Prepaid insurance 988 597 Prepaid medical affairs expenses 820 — Prepaid commercial planning 597 789 Prepaid professional services fees 432 198 Prepaid drug manufacturing costs 411 2,578 Prepaid software license fees 349 237 Prepaid rent 274 257 Other 1,129 866 Total prepaid expenses and other current assets $ 10,822 $ 11,307 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): September 30, December 31, Accrued clinical trial and drug manufacturing expenses $ 14,529 $ 2,213 Accrued payroll 3,641 3,932 Related party payable 105 1,926 Other accrued expenses 1,429 678 Other current liabilities 286 — Total accrued expenses and other current liabilities $ 19,990 $ 8,749 Related party payable represents amounts due to Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to manufacturing technology and know-how transfer services performed for atacicept pursuant to the license agreement between the Company and Ares (see Note 10).

Cash, Cash Equivalents And Mark

Cash, Cash Equivalents And Marketable Securities	9 Months Ended
	Sep. 30, 2024
Cash Equivalents And Marketable Securities [Abstract]
Cash, Cash Equivalents and Marketable Securities	4. CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES The Company’s cash equivalents and available-for-sale investment securities are classified within the fair value hierarchy as defined by authoritative guidance. Level 1 securities consist of highly liquid money market funds for which the carrying amount approximates the fair value of identical assets as quoted in the active markets. Level 2 securities, consisting of U.S. Treasuries, U.S. agency securities and corporate debt securities, are measured based on other observable inputs, including broker or dealer quotations or other valuations using observable market data. The Company’s debt securities are accounted for as available-for-sale securities. Unrealized gains and losses are reported as a component of other comprehensive income (loss). Fair value of the debt securities was $ 326.1 mi llion and $ 115.0 million as of September 30, 2024 and December 31, 2023, respectively. The following table presents the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): September 30, 2024 Fair Value Hierarchy Level Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Marketable Securities Money market funds Level 1 $ 24,814 $ - $ - $ 24,814 $ 24,814 $ - U.S. Government bonds Level 2 186,687 601 - 187,288 - 187,288 U.S. Government agency securities Level 2 5,996 3 - 5,999 - 5,999 Corporate debt securities Level 2 132,326 440 - 132,766 - 132,766 Total cash equivalents and marketable securities 349,823 1,044 - 350,867 24,814 326,053 Cash 2,442 Total $ 349,823 $ 1,044 $ - $ 350,867 $ 27,256 $ 326,053 December 31, 2023 Fair Value Hierarchy Level Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Marketable Securities Money market funds Level 1 $ 44,650 $ - $ - $ 44,650 $ 44,650 $ - U.S. Government bonds Level 2 63,619 70 ( 6 ) 63,683 - 63,683 U.S. Government agency securities Level 2 19,665 7 ( 14 ) 19,658 - 19,658 Corporate debt securities Level 2 31,500 194 - 31,694 - 31,694 Total cash equivalents and marketable securities 159,434 271 ( 20 ) 159,685 44,650 115,035 Cash 1,031 Total $ 159,434 $ 271 $ ( 20 ) $ 159,685 $ 45,681 $ 115,035 Marketable debt securities that had been in unrealized loss positions as of September 30, 2024, and December 31, 2023, were in an unrealized loss position for less than 12 months. Unrealized losses from marketable debt securities are primarily attributable to changes in interest rates. Management does not believe any remaining unrealized losses represent impairments based on evaluation of available evidence. The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates (in thousands): September 30, 2024 Due within one year $ 292,827 Due after one year to two years 33,226 Total marketable securities $ 326,053

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	5. LEASES The Company has entered into non-cancellable operating leases, including a sublease entered into in August 2024 for an office facility in Brisbane, California, that will serve as its corporate headquarters as of November 2024. This sublease expires in 2029 . The lease for the Company’s current corporate headquarters expires in November 2024. The Company also leases a facility in South San Francisco, California, that is subleased under a non-cancellable agreement to a third party, which ends concurrently with the original lease in September 2025. Net lease cost is as follows (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Operating lease cost $ 669 $ 644 $ 1,940 $ 1,933 Sublease income ( 487 ) ( 482 ) ( 1,462 ) ( 1,446 ) Net lease cost $ 182 $ 162 $ 478 $ 487 As of September 30, 2024, under the terms of the sublease agreement of the South San Francisco facility to a third party, the Company is entitled to receive future annual sublease payments as follows (in thousands): 2024 (remaining) 491 2025 1,496 Total sublease payments $ 1,987 As tenant under the South San Francisco facility lease, the Company remains responsible for minimum lease commitments of $ 2.5 million as of September 30, 2024. As of September 30, 2024, the future undiscounted lease payments under operating leases recognized in the condensed financial statements was $ 6.1 million. The weighted-average remaining lease term was 3.0 years and the weighted-average discount rate was 9.1 %. As of September 30, 2024, the Company had not executed any leases that were yet to commence.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Notes Payable	6. NOTES PAYABLE Notes payable consist of the following (in thousands): September 30, 2024 December 31, 2023 Maturity Effective Amount Effective Interest Rate Amount Collateralized note 2021-12 2027 14.59 % $ 5,000 14.73 % $ 5,000 Collateralized note 2022-11 2027 14.73 % 20,000 14.87 % 20,000 Collateralized note 2023-12 2027 15.23 % 25,000 15.37 % 25,000 Total borrowings 50,000 50,000 Accrued exit fee net of unamortized issuance costs 470 ( 123 ) Net carrying amount of debt $ 50,470 $ 49,877 The carrying amount of debt approximates fair value due to its variable interest rate. In December 2021, the Company entered into a non-revolving loan and security agreement (the Loan Agreement) with Oxford Finance. The Loan Agreement has a borrowing capacity of up to $ 50.0 million, of which $ 5.0 million was funded in December 2021, with the remaining credit facility available for draw until December 2022 , with maturity of the outstanding balance in December 2026. In November 2022, the Company entered into an amendment of the Loan Agreement. Among other changes, the amendment extended the scheduled expiration of the Loan Agreement from December 2022 to December 2023 and modified the reference rate from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (SOFR). In conjunction with the amendment, the Company borrowed an additional $ 20.0 million under the Loan Agreement. In December 2023, the Company borrowed the remaining $ 25.0 million under the Loan Agreement. As of September 30, 2024, the Company’s outstanding borrowing under the Loan Agreement was $ 50.0 million. In March 2023, upon achievement of a clinical data milestone, the Company elected to exercise a borrower option to extend the maturity of the outstanding loan by 12 months, from December 2026 to December 2027. The end date of the interest-only payment period was also extended by 12 months, from December 2025 to December 2026. The Company is permitted to prepay the loan, subject to certain conditions. Upon the maturity date or prepayment of the loan, the Company is required to pay an exit fee equal to 7 % of the aggregate principal amount of the loan. The variable interest rate on the drawn amount is adjusted SOFR plus 825 basis points, subject to a per annum floor rate of 8.25 %. The Loan Agreement contains a subjective acceleration clause in the case of an event of default. If such a matter occurs and is continuing, the lender may legally demand the outstanding principal and interest immediately due and payable. There are no financial covenants associated with the Loan Agreement and the loan is secured by the Company’s assets. The Loan Agreement is available for working capital, capital expenditures, and other general corporate purposes. Principal installments due on the notes are as follows (in thousands): Remainder of 2024 — 2025 — 2026 — 2027 50,000 Total long-term debt $ 50,000

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Common Stock	7. COMMON STOCK As of September 30, 2024, the Company’s amended and restated certificate of incorporation authorized the Company to issue 500,000,000 shares of Class A common stock and 14,600,000 shares of Class B common stock, each with a par value of $ 0.001 per share. Each share of Class A common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Class B common stock is non-voting. There are no shares of Class B common stock outstanding as of September 30, 2024. Common stockholders are entitled to receive dividends, as may be declared by the board of directors. Through September 30, 2024 , no cash dividends have been declared or paid. In June 2022, the Company filed a shelf registration statement on Form S-3 (File No. 333-265408) with the Securities and Exchange Commission, which permits the offering, issuance, and sale of up to a maximum aggregate offering price of $ 400.0 million of the Company’s common stock, preferred stock, debt securities and warrants. Up to a maximum of $ 150.0 million of the maximum aggregate offering price of $ 400.0 million may be issued and sold pursuant to an at-the-market financing facility under a sales agreement dated June 3, 2022, between the Company and Cowen and Company, LLC (Sales Agreement). In January 2024, the Company suspended and terminated the prospectus (the ATM Prospectus) related to the sale of its Class A common stock in an “at-the-market” offering pursuant to the terms of the Sales Agreement. As a result, the Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. Deferred costs of $ 0.3 million were recognized as general and administrative expense upon termination of the ATM Prospectus. In February 2023, the Company completed a follow-on public offering pursuant to which the Company issued and sold 16,428,572 shares of its Class A common stock at a public offering price of $ 7.00 per share, including 2,142,857 shares of Class A common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares. In February 2024, the Company completed a follow-on public offering pursuant to which the Company issued and sold 9,274,194 shares of its Class A common stock at a public offering price of $ 31.00 per share, including 1,209,677 shares of Class A common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares.

Stock Compensation

Stock Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock Compensation	8. STOCK COMPENSATION The 2021 Employee Stock Purchase Plan (ESPP) and the 2021 Equity Incentive Plan (2021 EIP) became effective in May 2021. The Company has reserved 1,152,463 and 6,873,404 shares of Class A common stock for issuance under the ESPP and 2021 EIP, respectively. The Company may not grant any additional awards under the 2017 Equity Incentive Plan (2017 EIP). The 2017 EIP will continue to govern outstanding equity awards granted thereunder. As of September 30, 2024 , there were 677,465 shares available for issuance under the 2021 EIP. In August 2024, the Company repurchased 4,450 unvested shares that were previously outstanding due to a stock option that was early exercised. The unvested shares were repurchased at the original exercise price of $ 2.8968 per share. 2017 EIP and 2021 EIP Stock option activity under the 2017 EIP and 2021 EIP was as follows: Number of Options Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (000s) Outstanding as of December 31, 2023 5,762,236 $ 9.42 7.66 $ 39,197 Granted 2,340,950 Exercised ( 1,167,790 ) Cancelled and forfeited ( 445,937 ) Outstanding as of September 30, 2024 6,489,459 $ 13.97 8.16 $ 196,198 Options exercisable as of September 30, 2024 2,646,618 $ 9.14 7.23 $ 92,781 Vested and expected to vest as of September 30, 2024 6,489,459 $ 13.97 8.16 $ 196,198 The aggregate intrinsic value of stock options exercised during the three and nine months ended September 30, 2024, was approximately $ 3.5 and $ 34.7 million, respectively. The weighted average grant date fair value of options granted during the three and nine months ended September 30, 2024 was $ 26.35 and $ 15.91 per share, respectively. ESPP The ESPP enables eligible employees to purchase shares of the Company’s common stock at the end of each offering period at a price equal to 85 % of the fair market value of the shares on the first trading day or the last trading day of the offering period, whichever is lower. Eligible employees generally include all employees. Share purchases are funded through payroll deductions of at least 1 % and up to 15 % of an employee’s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP increases automatically on the first day of each fiscal year, beginning on January 1, 2022, by a number equal to the lesser of 440,502 shares, 1 % of the total number of shares of the Company’s capital stock (including all classes of the Company’s common stock) outstanding on the last day of the calendar month prior to the date of the increase, or such lower number of shares (including no shares) approved by the Company’s board of directors. As of September 30, 2024, 88,752 shares have been issued pursuant to the ESPP. The ESPP generally provides for six-month consecutive offering periods beginning on September 14, 2021. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. Stock-based compensation expense related to the ESPP for the three and nine months ended September 30, 2024, was $ 0.1 mi llion and $ 0.2 million, respectively. Stock-Based Compensation Expense The following tables summarize the stock-based compensation expense for stock options and restricted stock units granted to employees and nonemployees and for ESPP stock-based compensation that was recorded in the Company’s condensed statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023. Three Months Ended Nine Months Ended 2024 2023 2024 2023 Research and development $ 2,261 $ 1,146 $ 5,888 $ 3,511 General and administrative 3,327 1,777 8,697 4,761 Total stock-based compensation expense $ 5,588 $ 2,923 $ 14,585 $ 8,272 Three Months Ended Nine Months Ended 2024 2023 2024 2023 Employees $ 4,791 $ 2,621 $ 12,923 $ 7,542 Nonemployees 797 302 1,662 730 Total stock-based compensation expense $ 5,588 $ 2,923 $ 14,585 $ 8,272 As of September 30, 2024, the Company had $ 41.3 million of unrecognized stock-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximatel y 2.7 years. The fair value of stock options granted during the three and nine months ended September 30, 2024 and 2023, was estimated using the Black-Scholes option pricing model based on the following weighted-average assumptions. Three Months Ended Nine Months Ended 2024 2023 2024 2023 Expected term (in years) 6 - 6.1 6.1 5.5 - 6.1 5.5 - 6.1 Expected volatility 70.3 % - 70.4 % 80.2 % 70.3 % - 73.2 % 79.5 % - 80.5 % Risk-free rate 3.6 % - 4.4 % 4.2 % 3.6 % - 4.6 % 3.4 % - 4.2 % Dividend yield — — — — Restricted Stock Units The Company grants restricted stock units (RSU) pursuant to the 2021 EIP and satisfies such grants through the issuance of its common stock. The following table shows RSU activity for the period ended September 30, 2024. Number of Shares Weighted Average Grant Date Fair Value per Share Unvested balance at December 31, 2023 131,679 $ 18.36 Granted 484,662 22.07 Vested ( 107,472 ) 18.52 Cancelled and forfeited ( 29,332 ) 17.86 Unvested balance at September 30, 2024 479,537 $ 22.10 For the nine months ended September 30, 2024, the Company recogniz ed $ 2.5 million of stock-based compensation for restricted stock units. As of September 30, 2024, the Company had $ 9.3 million of unrecognized stock-based compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of approximately 3.5 years. Inducement Plan In February 2024, the Company adopted the 2024 Inducement Plan (Inducement Plan). The Inducement Plan was adopted by the compensation committee of the Company’s board of directors without stockholder approval pursuant to Nasdaq Marketplace Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan, including stock options and restricted stock units, may only be granted to newly hired employees as a material inducement to accept employment with the Company. Awards granted under the Inducement Plan expire no later than ten years from the date of grant. An aggregate of 1,250,000 shares of common stock were reserved for issuance under the Inducement Plan. As of September 30, 2024, there were 738,025 shares available for issuance under the Inducement Plan.

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
	Sep. 30, 2024
Retirement Benefits [Abstract]
Employee Benefit Plans	9. EMPLOYEE BENEFIT PLANS The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. The Company contribute d $ 29,000 and $ 12,000 to the plan for the three months ended September 30, 2024 and 2023, respectively, and $ 180,000 a nd $ 138,000 for the nine months ended September 30, 2024 and 2023, respectively.

Licenses and Collaborations

Licenses and Collaborations	9 Months Ended
	Sep. 30, 2024
Licenses And Collaborations [Abstract]
Licenses and Collaborations	10. LICENSES AND COLLABORATIONS Ares Trading S.A. In October 2020, the Company entered into a license agreement with Ares (the Ares Agreement), pursuant to which the Company obtained an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. As consideration for the Ares Agreement, the Company paid a non-refundable license issue fee to Ares in the form of shares of redeemable convertible preferred stock valued at $ 13.1 million, resulting in Ares becoming a related party to the Company. The redeemable convertible preferred stock subsequently converted into 1,913,501 shares of Class A common stock in May 2021. In December 2020, the Company paid Ares a milestone payment of $ 25.0 million upon delivery and initiation of the transfer of specified information and materials. The non-refundable license issue fee and milestone payment were recorded to research and development expense in the period incurred. The Company is obligated to pay Ares aggregate milestone payments of up to $ 176.5 million upon the achievement of specified BLA filing or regulatory approval milestones, beginning with $ 15.0 million upon the first filing of an approval application and $ 20.0 million upon regulatory approval in the U.S., and up to $ 515.0 million upon the achievement of specified commercial milestones, beginning with $ 15.0 million if worldwide aggregate annual net sales reach $ 250 million and $ 50.0 million if worldwide aggregate annual net sales reach $ 500 million. Subsequent to the effective date of the Ares Agreement, Ares is performing manufacturing technology and know-how transfer to the Company. The Company recorded related party expense of $ 0.1 m illion and $ 0.4 million to Ares for these services during the three months ended September 30, 2024 and 2023, respectively, an d $ 0.3 m illion and $ 2.4 million during the nine months ended September 30, 2024 and 2023, respectively. These amounts are included in research and development expenses on the statements of operations and comprehensive loss. Commencing on the first commercial sale of licensed products, the Company is obligated to pay Ares tiered royalties of low double-digit to mid-teen percentages on annual net sales of the licensed products covered by the license. The Company is obligated to pay royalties on a licensed product-by-licensed product and country-by-country basis from the first commercial sale of a product in a country until the latest of (i) 15 years after the first commercial sale of such licensed product in such country; (ii) the expiration of the last valid claim of a licensed patent that covers such licensed product in, or its use, importation or manufacture with respect to, such country; and (iii) expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such product. If the Company were to sublicense its rights under the Ares Agreement, the Company would be obligated to pay Ares a percentage ranging from the mid-single-digit to the low double-digits of specified sublicensing income received. Amplyx Pharmaceuticals, Inc. In December 2021, the Company entered into an asset purchase agreement (the Amplyx Agreement) with Amplyx Pharmaceuticals, Inc. (Amplyx), a wholly owned subsidiary of Pfizer Inc. Pursuant to the terms of the Amplyx Agreement, the Company paid $ 5.0 million to Amplyx to purchase assets relating to an anti-BKV monoclonal antibody referred to as MAU868 for the treatment of BKV infection pursuant to a License Agreement between Amplyx and Novartis International Pharmaceutical AG (Novartis). In addition, the Company recognized a $ 2.0 million contingent milestone obligation as an assumed liability related to the asset purchase. The acquisition cost of $ 7.0 million was recorded as research and development expense in the statement of operations and comprehensive loss on the acquisition date. In connection with the Amplyx asset purchase, Amplyx assigned the Exclusive License Agreement between Amplyx and Novartis (the Novartis License) and Manufacturing and Supply Agreements to the Company. Under the Novartis License, the Company has exclusive worldwide rights from Novartis to develop, manufacture and commercialize MAU868. The Company will be solely responsible for all research, development, regulatory, manufacturing and commercialization activities of MAU868. Under the Amplyx Agreement, the Company is obligated to make future milestone payments to Amplyx and Novartis upon the achievement of specified development, regulatory and commercial milestones. In September 2022, the Company and Novartis entered into an amendment to the Novartis License to modify the terms of future milestone payments. Pursuant to this amendment, the Company issued 283,034 shares of Class A common stock to Novartis in exchange for a reduction of $ 7.0 million in contingent future development milestones, including the $ 2.0 million contingent milestone obligation accrued by the Company in December 2021. The value of the shares issued was $ 5.7 million based on the closing market value of the Company’s Class A common stock as of the effective date of the amendment. The Company is obligated to make future milestone payments of up to $ 7.0 million and $ 62.0 million to Amplyx and Novartis, respectively, contingent upon the achievement of specified development, regulatory and commercial milestones. In the event that MAU868 is commercialized, the Company will be obligated to pay royalties to Amplyx and Novartis based on net sales by country and by product.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company believes that there are no actions pending which would have a material adverse effect on its results of operations, financial condition, or cash flows. Indemnifications As of September 30, 2024, the Company did not have any material indemnification claims that were probable or reasonably possible, and consequently no related liabilities have been recorded. Employee Agreements The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including severance and accelerated vesting of equity incentives. Development and Manufacturing Services Agreements The Company enters into development and manufacturing contracts with vendors in the conduct of our business. Contracts with these vendors may be terminated at the Company’s option, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would be obligated to pay for the products or services that had been provided or received at the time the termination became effective, and potentially additional compensation based upon the period of time remaining between the date of notice of cancellation and the scheduled manufacturing.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	12. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis). Three Months Ended Nine Months Ended 2024 2023 2024 2023 Class A common stock options issued and outstanding 6,489,459 5,732,181 6,489,459 5,732,181 Unvested RSUs 479,537 132,616 479,537 132,616 Total 6,968,996 5,864,797 6,968,996 5,864,797

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	13. RELATED PARTY TRANSACTIONS In October 2020, the Company entered into the Ares Agreement with Ares, pursuant to which the Company obtained an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. Related party transactions and balances in the current periods presented are described in Note 3 and Note 10. Sofinnova Venture Partners X, L.P. (SVP X) is an investment fund in which Maha Katabi (Dr. Katabi), a member of the Company’s board of directors, has a pecuniary interest. SVP X completed transactions in the Company’s common stock within a six-month period ended March 25, 2024. The transactions included both purchases and sales of shares of the Company’s common stock that may be matchable for purposes of Section 16(b) of the Securities Exchange Act of 1934, as amended. These transactions could be deemed to have resulted in short-swing profits to Dr. Katabi of $ 36,620 . Dr. Katabi voluntarily agreed to disgorge the profits and has paid $ 36,620 to the Company as a result of these transactions.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENT	14. SUBSEQUENT EVENT On October 31, 2024, the Company completed a follow-on public offering pursuant to which the Company issued and sold 7,142,858 shares of its common stock at an offering price of $ 42.00 per share. On November 5, 2024, the Company issued an additional 1,071,428 shares of common stock at $ 42.00 per share, pursuant to the underwriters’ option. The Company received aggregate net proceeds of approximately $ 323.6 million, after deducting underwriting discounts and commissions of $ 20.7 million, and offering costs of approximately $ 0.7 million.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (the SEC) regarding interim financial reporting. The U.S. dollar is the Company’s functional and reporting currency.
Unaudited Condensed Financial Statements	Unaudited Condensed Financial Statements In the opinion of management, the unaudited condensed financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the periods presented. Interim results are not necessarily indicative of results for a full year or any other period. The information included in this Form 10-Q should be read in conjunction with the audited financial statements and related notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 27, 2024.
Emerging Growth Company Status	Emerging Growth Company Status T he Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the accrual of research and development expenses, valuation of equity awards for stock-based compensation, determination of incremental borrowing rate for operating leases, the valuation allowance for deferred tax assets, and fair value of marketable and non-marketable securities. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates.
Concentrations of Credit Risk and Other Risks and Uncertainties	Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations. The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fails to satisfy the Company’s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect operating results. The Company’s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies from the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 .
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard update clarifies the guidance in Topic 210, related to measuring the fair value of an equity security subject to contractual sale restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The guidance is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company adopted this standard on January 1, 2024, and it did not have a material impact on the Company’s condensed financial statements or related disclosures .
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements and requires enhanced disclosures related to significant segment expenses regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. This ASU will result in the required additional disclosures being included in the Company’s financial statements upon adoption. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in the Company’s financial statements upon adoption .

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	9 Months Ended
	Sep. 30, 2024
Other Financial Statement Information [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, Prepaid clinical trial costs $ 3,825 $ 5,273 Interest income receivable 1,997 512 Prepaid insurance 988 597 Prepaid medical affairs expenses 820 — Prepaid commercial planning 597 789 Prepaid professional services fees 432 198 Prepaid drug manufacturing costs 411 2,578 Prepaid software license fees 349 237 Prepaid rent 274 257 Other 1,129 866 Total prepaid expenses and other current assets $ 10,822 $ 11,307
Schedule of Accrued Expenses And Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): September 30, December 31, Accrued clinical trial and drug manufacturing expenses $ 14,529 $ 2,213 Accrued payroll 3,641 3,932 Related party payable 105 1,926 Other accrued expenses 1,429 678 Other current liabilities 286 — Total accrued expenses and other current liabilities $ 19,990 $ 8,749

Cash, Cash Equivalents And Ma_2

Cash, Cash Equivalents And Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Cash Equivalents And Marketable Securities [Abstract]
Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities	The following table presents the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): September 30, 2024 Fair Value Hierarchy Level Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Marketable Securities Money market funds Level 1 $ 24,814 $ - $ - $ 24,814 $ 24,814 $ - U.S. Government bonds Level 2 186,687 601 - 187,288 - 187,288 U.S. Government agency securities Level 2 5,996 3 - 5,999 - 5,999 Corporate debt securities Level 2 132,326 440 - 132,766 - 132,766 Total cash equivalents and marketable securities 349,823 1,044 - 350,867 24,814 326,053 Cash 2,442 Total $ 349,823 $ 1,044 $ - $ 350,867 $ 27,256 $ 326,053 December 31, 2023 Fair Value Hierarchy Level Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash and Cash Equivalents Marketable Securities Money market funds Level 1 $ 44,650 $ - $ - $ 44,650 $ 44,650 $ - U.S. Government bonds Level 2 63,619 70 ( 6 ) 63,683 - 63,683 U.S. Government agency securities Level 2 19,665 7 ( 14 ) 19,658 - 19,658 Corporate debt securities Level 2 31,500 194 - 31,694 - 31,694 Total cash equivalents and marketable securities 159,434 271 ( 20 ) 159,685 44,650 115,035 Cash 1,031 Total $ 159,434 $ 271 $ ( 20 ) $ 159,685 $ 45,681 $ 115,035
Schedule of Estimated Fair Value of Investments in Available-for-sale Marketable Debt Securities	The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates (in thousands): September 30, 2024 Due within one year $ 292,827 Due after one year to two years 33,226 Total marketable securities $ 326,053

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Lease Cost	Net lease cost is as follows (in thousands): Three Months Ended Nine Months Ended 2024 2023 2024 2023 Operating lease cost $ 669 $ 644 $ 1,940 $ 1,933 Sublease income ( 487 ) ( 482 ) ( 1,462 ) ( 1,446 ) Net lease cost $ 182 $ 162 $ 478 $ 487
Schedule of Receivable Future Annual Sublease Payments	As of September 30, 2024, under the terms of the sublease agreement of the South San Francisco facility to a third party, the Company is entitled to receive future annual sublease payments as follows (in thousands): 2024 (remaining) 491 2025 1,496 Total sublease payments $ 1,987

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consist of the following (in thousands): September 30, 2024 December 31, 2023 Maturity Effective Amount Effective Interest Rate Amount Collateralized note 2021-12 2027 14.59 % $ 5,000 14.73 % $ 5,000 Collateralized note 2022-11 2027 14.73 % 20,000 14.87 % 20,000 Collateralized note 2023-12 2027 15.23 % 25,000 15.37 % 25,000 Total borrowings 50,000 50,000 Accrued exit fee net of unamortized issuance costs 470 ( 123 ) Net carrying amount of debt $ 50,470 $ 49,877
Schedule Principal Installments Due	Principal installments due on the notes are as follows (in thousands): Remainder of 2024 — 2025 — 2026 — 2027 50,000 Total long-term debt $ 50,000

Stock Compensation (Tables)

Stock Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Share-based Compensation Arrangements by Share-based Payment Award	Stock option activity under the 2017 EIP and 2021 EIP was as follows: Number of Options Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (000s) Outstanding as of December 31, 2023 5,762,236 $ 9.42 7.66 $ 39,197 Granted 2,340,950 Exercised ( 1,167,790 ) Cancelled and forfeited ( 445,937 ) Outstanding as of September 30, 2024 6,489,459 $ 13.97 8.16 $ 196,198 Options exercisable as of September 30, 2024 2,646,618 $ 9.14 7.23 $ 92,781 Vested and expected to vest as of September 30, 2024 6,489,459 $ 13.97 8.16 $ 196,198
Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following tables summarize the stock-based compensation expense for stock options and restricted stock units granted to employees and nonemployees and for ESPP stock-based compensation that was recorded in the Company’s condensed statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023. Three Months Ended Nine Months Ended 2024 2023 2024 2023 Research and development $ 2,261 $ 1,146 $ 5,888 $ 3,511 General and administrative 3,327 1,777 8,697 4,761 Total stock-based compensation expense $ 5,588 $ 2,923 $ 14,585 $ 8,272 Three Months Ended Nine Months Ended 2024 2023 2024 2023 Employees $ 4,791 $ 2,621 $ 12,923 $ 7,542 Nonemployees 797 302 1,662 730 Total stock-based compensation expense $ 5,588 $ 2,923 $ 14,585 $ 8,272
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of stock options granted during the three and nine months ended September 30, 2024 and 2023, was estimated using the Black-Scholes option pricing model based on the following weighted-average assumptions. Three Months Ended Nine Months Ended 2024 2023 2024 2023 Expected term (in years) 6 - 6.1 6.1 5.5 - 6.1 5.5 - 6.1 Expected volatility 70.3 % - 70.4 % 80.2 % 70.3 % - 73.2 % 79.5 % - 80.5 % Risk-free rate 3.6 % - 4.4 % 4.2 % 3.6 % - 4.6 % 3.4 % - 4.2 % Dividend yield — — — —
Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity	The following table shows RSU activity for the period ended September 30, 2024. Number of Shares Weighted Average Grant Date Fair Value per Share Unvested balance at December 31, 2023 131,679 $ 18.36 Granted 484,662 22.07 Vested ( 107,472 ) 18.52 Cancelled and forfeited ( 29,332 ) 17.86 Unvested balance at September 30, 2024 479,537 $ 22.10

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Summary of Dilutive Shares Excluded From Computation of Diluted Net Loss Per Share	The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis). Three Months Ended Nine Months Ended 2024 2023 2024 2023 Class A common stock options issued and outstanding 6,489,459 5,732,181 6,489,459 5,732,181 Unvested RSUs 479,537 132,616 479,537 132,616 Total 6,968,996 5,864,797 6,968,996 5,864,797

Organization and Description _2

Organization and Description of the Business - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accumulated deficit	$ (417,825)	$ (309,102)
Cash and cash equivalents and marketable securities	$ 353,300

Other Financial Statement Inf_3

Other Financial Statement Information - Schedule Of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Other Financial Statement Information [Abstract]
Prepaid clinical trial costs	$ 3,825	$ 5,273
Interest income receivable	1,997	512
Prepaid insurance	988	597
Prepaid medical affairs expenses	820	0
Prepaid commercial planning	597	789
Prepaid professional services fees	432	198
Prepaid drug manufacturing costs	411	2,578
Prepaid software license fees	349	237
Prepaid rent	274	257
Other	1,129	866
Total prepaid expenses and other current assets	$ 10,822	$ 11,307

Other Financial Statement Inf_4

Other Financial Statement Information - Schedule Of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accrued clinical trial and drug manufacturing expenses	$ 14,529	$ 2,213
Accrued payroll	3,641	3,932
Other accrued expenses	1,429	678
Other current liabilities	286	0
Total accrued expenses and other current liabilities	19,990	8,749
Related Party [Member]
Related party payable	$ 105	$ 1,926

Cash, Cash Equivalents And Ma_3

Cash, Cash Equivalents And Marketable Securities - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Cash Equivalents And Marketable Securities [Abstract]
Fair value of the debt securities	$ 326.1	$ 115

Cash, Cash Equivalents And Ma_4

Cash, Cash Equivalents And Marketable Securities - Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Marketable Securities [Line Items]
Amortized Cost	$ 349,823	$ 159,434
Unrealized Gains	1,044	271
Unrealized Losses	0	(20)
Estimated Fair Value	350,867	159,685
Cash and Cash Equivalents	27,256	45,681
Marketable Securities	326,053	115,035
Cash Equivalents and Marketable Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	349,823	159,434
Unrealized Gains	1,044	271
Unrealized Losses	0	(20)
Estimated Fair Value	350,867	159,685
Cash and Cash Equivalents	24,814	44,650
Marketable Securities	326,053	115,035
Money Market Funds [Member] | Level 1
Marketable Securities [Line Items]
Amortized Cost	24,814	44,650
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	24,814	44,650
Cash and Cash Equivalents	24,814	44,650
Marketable Securities	0	0
US Government Bonds [Member] | Level 2
Marketable Securities [Line Items]
Amortized Cost	186,687	63,619
Unrealized Gains	601	70
Unrealized Losses	0	(6)
Estimated Fair Value	187,288	63,683
Cash and Cash Equivalents	0	0
Marketable Securities	187,288	63,683
US Government Agency Securities [Member] | Level 2
Marketable Securities [Line Items]
Amortized Cost	5,996	19,665
Unrealized Gains	3	7
Unrealized Losses	0	(14)
Estimated Fair Value	5,999	19,658
Cash and Cash Equivalents	0	0
Marketable Securities	5,999	19,658
Corporate Debt Securities [Member] | Level 2
Marketable Securities [Line Items]
Amortized Cost	132,326	31,500
Unrealized Gains	440	194
Unrealized Losses	0	0
Estimated Fair Value	132,766	31,694
Cash and Cash Equivalents	0	0
Marketable Securities	132,766	31,694
Cash [Member]
Marketable Securities [Line Items]
Cash and Cash Equivalents	$ 2,442	$ 1,031

Cash, Cash Equivalents And Ma_5

Cash, Cash Equivalents And Marketable Securities - Schedule of Estimated Fair Value of Marketable Securities by Stated Contractual Maturities (Detail) $ in Thousands	Sep. 30, 2024 USD ($)
Cash Equivalents And Marketable Securities [Abstract]
Due within one year	$ 292,827
Due after one year to two years	33,226
Total marketable securities	$ 326,053

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Operating lease cost	$ 669	$ 644	$ 1,940	$ 1,933
Sublease income	(487)	(482)	(1,462)	(1,446)
Net lease cost	$ 182	$ 162	$ 478	$ 487

Leases - Schedule of Receivable

Leases - Schedule of Receivable Future Annual Sublease Payments (Detail) $ in Thousands	Sep. 30, 2024 USD ($)
Leases [Abstract]
2024 (remaining)	$ 491
2025	1,496
Total sublease payments	$ 1,987

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Information Related to Operating Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Cash payments for operating leases	$ 2,343	$ 2,238

Leases - Additional Information

Leases - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($)
Leases [Abstract]
Lease expiring period	2029
Lease payments under operating leases	$ 6.1
Operating lease, weighted average remaining lease term	3 years
Operating lease, weighted average discount rate, percent	9.10%
Operating lease minimum future commitments	$ 2.5

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total Borrowings	$ 50,000	$ 50,000
Accrued exit fee net of unamortized issuance costs	470	(123)
Net carrying amount of debt	$ 50,470	$ 49,877
LIBOR [Member] | Collateralized note 2021-12
Debt Instrument [Line Items]
Collateralized debt instrument maturity date	2027
Collateralized note , Effective interest rate	14.59%	14.73%
Collateralized note ,Amount	$ 5,000	$ 5,000
SOFR [Member] | Collateralized note 2022-11
Debt Instrument [Line Items]
Collateralized debt instrument maturity date	2027
Collateralized note , Effective interest rate	14.73%	14.87%
Collateralized note ,Amount	$ 20,000	$ 20,000
SOFR [Member] | Collateralized note 2023-12
Debt Instrument [Line Items]
Collateralized debt instrument maturity date	2027
Collateralized note , Effective interest rate	15.23%	15.37%
Collateralized note ,Amount	$ 25,000	$ 25,000

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2021	Dec. 31, 2023
Debt Instrument [Line Items]
Carrying amount of debt outstanding	$ 50,000
Base Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	8.25%
Loan Facility [Member]
Debt Instrument [Line Items]
Revolving credit facility with borrowing capacity		$ 20,000
Remaining capacity available			$ 25,000
Additional borrowing capacity		50,000
Proceeds from line of credit		$ 5,000
Carrying amount of debt outstanding	$ 50,000
Debt facility payments description	The end date of the interest-only payment period was also extended by 12 months, from December 2025 to December 2026.
Prepayment of the loan	7%
Amended Loan Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Expiration Date		Dec. 31, 2022

Note Payable - Schedule Princip

Note Payable - Schedule Principal Installments Due (Detail) $ in Thousands	Sep. 30, 2024 USD ($)
Debt Disclosure [Abstract]
2027	$ 50,000
Total long-term debt	$ 50,000

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)			1 Months Ended	9 Months Ended
	Feb. 06, 2024	Feb. 06, 2023	Jan. 31, 2024	Sep. 30, 2024	Sep. 30, 2022	Dec. 31, 2023
Class Of Stock [Line Items]
Maximum aggregate offering price of common stock, preferred stock, debt securities and warrants				$ 400,000,000
Cowen and Company, LLC [Member] | 2022 ATM facility [Member]
Class Of Stock [Line Items]
Deferred costs, written off			$ 300,000
Cowen and Company, LLC [Member] | Maximum [Member] | 2022 ATM facility [Member]
Class Of Stock [Line Items]
Maximum aggregate offering price of common stock, preferred stock, debt securities and warrants				$ 150,000,000
Common Class A [Member]
Class Of Stock [Line Items]
Common stock, shares authorized				500,000,000		500,000,000
Common stock, Par value				$ 0.001		$ 0.001
Common stock conversion basis				one
Cash dividends				$ 0
Stock shares issued during the period new issues shares	1,209,677	2,142,857
Company shares issued					283,034
Common stock, Shares outstanding				55,026,111		44,452,161
Common Class A [Member] | Follow-on Public Offering [Member]
Class Of Stock [Line Items]
Stock shares issued during the period new issues shares	9,274,194	16,428,572
Sale of stock, price per share	$ 31	$ 7
Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized				14,600,000
Common stock, Par value				$ 0.001
Cash dividends				$ 0
Common stock, Shares outstanding				0

Stock Compensation - Additional

Stock Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2024	Feb. 29, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Aug. 31, 2024	May 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation arrangement by share based payment award, Options exercised in period, Total intrinsic value			$ 3,500		$ 34,700
Number of shares issued under share-based payment arrangement					88,752
Stock-based compensation expense			$ 5,588	$ 2,923	$ 14,585	$ 8,272
Unvested Shares Repurchased	4,450
Exercise Price of Repurchased Unvested Shares							$ 2.8968
Employee Stock Purchase Plan ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock capital, Shares reserved for future issuance								1,152,463
2021 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock capital, Shares reserved for future issuance								6,873,404
Share-based compensation arrangement by share-based payment award, Number of shares available for issuance			677,465		677,465
2017 and 2021 Amended Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation arrangement by share based payment award, Options granted in period, Weighted average grant date fair value			$ 26.35		$ 15.91
2024 Inducement Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock capital, Shares reserved for future issuance		1,250,000
Share-based compensation arrangement by share-based payment award, Number of shares available for issuance			738,025		738,025
Expiration period		10 years
Unvested Stock Options And Restricted Stock Awards [Member] | 2017 and 2021 Amended Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, Nonvested awards, Compensation cost not yet recognized Stock options and equity instruments other than options			$ 41,300		$ 41,300
Share based compensation, Nonvested awards, Compensation cost not yet recognized period of recognition stock options and equity instruments other than options					2 years 8 months 12 days
Unvested Stock Options And Restricted Stock Unit [Member] | 2017 and 2021 Amended Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, Nonvested awards, Compensation cost not yet recognized Stock options and equity instruments other than options			$ 9,300		$ 9,300
Restricted Stock [Member] | Unvested Stock Options And Restricted Stock Unit [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, Nonvested awards, Compensation cost not yet recognized period of recognition stock options and equity instruments other than options					3 years 6 months
ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock Percent of Fair Market Value					85%
Share purchases funded through payroll deductions for employee's eligible minimum annual compensation, percentage					1%
Share purchases funded through payroll deductions for employee's eligible maximum annual compensation, percentage			15%		15%
Potential increase in shares reserved for future issuance (in shares)					440,502
Potential increase in shares reserved for future issuance as percentage of outstanding share					1%
Stock-based compensation expense			$ 100		$ 200
Restricted Stock Units (RSUs) [Member] | 2017 and 2021 Amended Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense					$ 2,500

Stock Compensation - Summary of

Stock Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Details) - 2017 EIP And 2021 EIP [Member] $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Beginning	5,762,236
Number of Options, Granted	2,340,950
Number of Options, Exercised	(1,167,790)
Number of Options, Cancelled and forfeited	(445,937)
Number of Options, Ending	6,489,459	5,762,236
Number of Options, Options exercisable	2,646,618
Number of Options, Vested and expected to vest	6,489,459
Weighted Average Exercise Price, Opening balance | $ / shares	$ 9.42
Weighted Average Exercise Price, Ending balance | $ / shares	13.97	$ 9.42
Weighted Average Exercise Price, Option exercisable | $ / shares	9.14
Weighted Average Exercise Price, Vested and expected to vest | $ / shares	$ 13.97
Weighted Average Remaining Contractual Life	8 years 1 month 28 days	7 years 7 months 28 days
Weighted Average Remaining Contractual Life, Options exercisable	7 years 2 months 23 days
Weighted Average Remaining Contractual Life, Vested and expected to vest	8 years 1 month 28 days
Aggregate Intrinsic Value | $	$ 196,198	$ 39,197
Aggregate Intrinsic Value, Options exercisable | $	92,781
Aggregate Intrinsic Value, Vested and expected to vest | $	$ 196,198

Stock compensation - Summary _2

Stock compensation - Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 5,588	$ 2,923	$ 14,585	$ 8,272
Employees [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	4,791	2,621	12,923	7,542
Nonemployees [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	797	302	1,662	730
Research and development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	2,261	1,146	5,888	3,511
General and administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 3,327	$ 1,777	$ 8,697	$ 4,761

Stock Compensation - Schedule o

Stock Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)		6 years 1 month 6 days
Expected volatility, Minimum	70.30%		70.30%	79.50%
Expected volatility		80.20%
Expected volatility, Maximum	70.40%		73.20%	80.50%
Risk-free rate, Minimum	3.60%		3.60%	3.40%
Risk-free rate		4.20%
Risk-free rate, Maximum	4.40%		4.60%	4.20%
Minimum [Member]
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)	6 years		5 years 6 months	5 years 6 months
Maximum [Member]
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)	6 years 1 month 6 days		6 years 1 month 6 days	6 years 1 month 6 days

Stock Compensation - Summary _3

Stock Compensation - Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested as of December 31, 2023 | shares	131,679
Granted | shares	484,662
Vested | shares	(107,472)
Cancelled and forfeited | shares	(29,332)
Unvested as of September 30, 2024 | shares	479,537
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 18.36
Weighted Average Grant Date Fair Value, Granted | $ / shares	22.07
Weighted Average Grant Date Fair Value, Vested | $ / shares	18.52
Weighted Average Grant Date Fair Value, Cancelled and Forfeited | $ / shares	17.86
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 22.1

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Retirement Benefits [Abstract]
Employer contributions	$ 29,000	$ 12,000	$ 180,000	$ 138,000

Licenses and Collaborations - A

Licenses and Collaborations - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended			12 Months Ended
	Oct. 31, 2020	May 31, 2021	Dec. 31, 2020	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021
License and Collaborations [Line Items]
Research and development				$ 40,314	$ 16,100	$ 92,825	$ 57,440
Ares Trading S A [Member]
License and Collaborations [Line Items]
Aggregate annual sales1			$ 250,000
Aggregate annual sales net2			500,000
Ares Trading S A [Member] | Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable			15,000
Ares Trading S A [Member] | Aggregate Annual Net Sales Reach $250 Million [Member]
License and Collaborations [Line Items]
Milestone payable on aggregate annual sales1			15,000
Ares Trading S A [Member] | Aggregate Annual Net Sales Reach $500 Million [Member]
License and Collaborations [Line Items]
Milestone payable on aggregate annual sales2			50,000
Ares Agreement [Member] | Ares Trading S A [Member]
License and Collaborations [Line Items]
Milestone payments payable			25,000
Related party transaction, expenses from transactions with related party				100	$ 400	300	$ 2,400
Ares Agreement [Member] | Ares Trading S A [Member] | Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable			176,500
Ares Agreement [Member] | Ares Trading S A [Member] | Achievement Of Specified Commercial Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable			515,000
Ares Agreement [Member] | Ares Trading S A [Member] | Regulatory Approval In The U.S [Member]
License and Collaborations [Line Items]
Milestone payments payable			$ 20,000
Amplyx Agreement [Member]
License and Collaborations [Line Items]
Milestone payments payable									$ 2,000
Acquisition cost									5,000
Research and development									7,000
Reduction in contingent future development								$ 7,000
Contingent milestone obligation accrued									$ 2,000
Company shares issued								$ 5,700
Amplyx Agreement [Member] | Amplyx and Novartis [Member] | Achievement of Various Clinical Development and Regulatory Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable				7,000		7,000
Novartis [Member] | Amplyx and Novartis [Member] | Achievement of Various Clinical Development and Regulatory Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable				$ 62,000		$ 62,000
Series C [Member] | Ares Agreement [Member] | Ares Trading S A [Member]
License and Collaborations [Line Items]
Temporary equity stock shares issued during the period shares		1,913,501
Temporary equity shares issued during the period value	$ 13,100
Common Class A [Member]
License and Collaborations [Line Items]
Company shares issued								283,034

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	6,968,996	5,864,797	6,968,996	5,864,797
Class A Common Stock Options Issued and Outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	6,489,459	5,732,181	6,489,459	5,732,181
Unvested Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	479,537	132,616	479,537	132,616

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Related Party Transactions [Abstract]
Proceeds from short swing profits	$ 36,620
Proceeds from disgorgement representing short swing profits	$ 36,620

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Nov. 05, 2024	Oct. 31, 2024	Feb. 06, 2024	Feb. 06, 2023	Oct. 30, 2024
Common Class A [Member]
Subsequent Event [Line Items]
Stock shares issued during the period shares			1,209,677	2,142,857
Common Class A [Member] | Follow-on Public Offering [Member]
Subsequent Event [Line Items]
Sale of stock, price per share			$ 31	$ 7
Stock shares issued during the period shares			9,274,194	16,428,572
Subsequent Event
Subsequent Event [Line Items]
Sale of stock net consideration received on the transaction	$ 323.6
Underwriting discounts and commissions	20.7
Payments of offering costs	$ 0.7
Subsequent Event | Common Stock [Member]
Subsequent Event [Line Items]
Sale of stock, price per share					$ 42
Stock shares issued during the period shares		7,142,858
Subsequent Event | Common Stock [Member] | Over-Allotment Option [Member]
Subsequent Event [Line Items]
Sale of stock, price per share	$ 42
Stock shares issued during the period shares	1,071,428